ProfileGDS5678 / 1425106_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 86% 83% 87% 85% 85% 85% 84% 82% 83% 84% 82% 83% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7560481
GSM967853U87-EV human glioblastoma xenograft - Control 26.5477686
GSM967854U87-EV human glioblastoma xenograft - Control 36.0727583
GSM967855U87-EV human glioblastoma xenograft - Control 46.9407587
GSM967856U87-EV human glioblastoma xenograft - Control 56.4136785
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.1706185
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.1581885
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1432984
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9528582
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.059183
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.211484
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0389982
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.1190383
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.949582